Prescription-Event Monitoring in New Zealand
作者： Mira Harrison-Woolrych
DOI: 10.1002/9781118820186.CH23
关键词:
摘要:
sci-hub.se 参考文章(50)
Mira Harrison-Woolrych, Janelle Ashton, Psychiatric Adverse Events Associated with Varenicline Drug Safety. ,vol. 34, pp. 763- 772 ,(2011) , 10.2165/11594450-000000000-00000
DM Coulter, PI Pillans, Fluoxetine and hyponatraemia--a potential hazard in the elderly. The New Zealand Medical Journal. ,vol. 107, pp. 85- 86 ,(1994)
Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry. ,vol. 152, pp. 122- 125 ,(1995) , 10.1176/AJP.152.1.122
DM Coulter, PI Pillans, Angiotensin-Converting Enzyme-Inhibitors and Psoriasis The New Zealand Medical Journal. ,vol. 106, pp. 392- 393 ,(1993)
Mira Harrison-Woolrych, Patient Reporting Encouraged during Monitoring of Dapoxetine in New Zealand Drug Safety. ,vol. 34, pp. 1115- 1116 ,(2011) , 10.2165/11596010-000000000-00000
Ming Tan, Mira Harrison-Woolrych, Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme. European Journal of Clinical Pharmacology. ,vol. 69, pp. 1195- 1196 ,(2013) , 10.1007/S00228-012-1458-4
Peter W. Beggs, David W.J. Clark, Sheila M. Williams, David M. Coulter, A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). British Journal of Clinical Pharmacology. ,vol. 47, pp. 99- 104 ,(1999) , 10.1046/J.1365-2125.1999.00846.X
Mira Harrison-Woolrych, Helen Paterson, Ming Tan, Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study Pharmacoepidemiology and Drug Safety. ,vol. 22, pp. 1086- 1092 ,(2013) , 10.1002/PDS.3489
M. Harrison-Woolrych, Safety data from New Zealand BMJ. ,vol. 339, pp. 117- 118 ,(2009) , 10.1136/BMJ.B5654
Mira Harrison-Woolrych, Janelle Ashton, Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand. Pharmacoepidemiology and Drug Safety. ,vol. 19, pp. 949- 953 ,(2010) , 10.1002/PDS.2003